<SEC-DOCUMENT>0001144204-13-045465.txt : 20130814
<SEC-HEADER>0001144204-13-045465.hdr.sgml : 20130814
<ACCEPTANCE-DATETIME>20130814093424
ACCESSION NUMBER:		0001144204-13-045465
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130814
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130814
DATE AS OF CHANGE:		20130814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		131035284

	BUSINESS ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v352913_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
August 14, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="color: black">Nevada</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="color: black">1-12584</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="color: black">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="color: black">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">(Commission File No.)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">155 Gibbs Street, Ste. 412</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (734) 332-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT> <FONT STYLE="color: black">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT> <FONT STYLE="color: black">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT> <FONT STYLE="color: black"><FONT STYLE="color: black">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT> <FONT STYLE="color: black"><FONT STYLE="color: black">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.02 - Results of Operations and
Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 14, 2013, Synthetic Biologics, Inc., a Nevada corporation,
(the &ldquo;Registrant&quot;) issued the attached press release that included financial information for the three and six months ended June 30, 2013. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information contained
in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant&rsquo;s
registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="color: black">(d)&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="color: black">Exhibits.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><FONT STYLE="color: black">Exhibit 99.1 Press Release issued by Synthetic Biologics, Inc. dated August 14, 2013.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt"></P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="color: black">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD><FONT STYLE="color: black">Date: August 14, 2013</FONT></TD>
    <TD><FONT STYLE="color: black">By: <U>/s/ C. Evan Ballantyne</U></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Name: C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Title: Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt"></P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; text-align: center"><FONT STYLE="color: black"><U>Exhibit No .</U></FONT></TD>
    <TD STYLE="width: 85%"><FONT STYLE="color: black"><U>Exhibits.</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="color: black">99.1</FONT></TD>
    <TD><FONT STYLE="color: black">Press Release issued by Synthetic Biologics, Inc. dated August 14, 2013</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v352913_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Reports Second Quarter
2013 Financial Results and Operational Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">-- Progress Cited On Three Infectious
Disease Programs, Including Two Programs in Collaboration</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">with Intrexon Corporation; C.
difficile Prophylactic is Lead Anti-Infective Candidate --</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, August 14, 2013 &ndash;</B>
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious
diseases, today reported financial results for the three and six months ended June 30, 2013 and provided an operational update.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s
development portfolio includes three anti-infective product candidates, two of which are being developed in collaboration with
Intrexon Corporation (NYSE: XON), and an oral multiple sclerosis (MS) product candidate in Phase II development. The relapsing-remitting
MS clinical trial is expected to be completed in January 2014, with key data to be released shortly thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Conference
call scheduled for 4:00pm EDT today. To participate, please call</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1-800-860-2442 (U.S. toll free), 1-866-605-3852
(Canada), or +1 412-858-4600 (International),</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>fifteen minutes before the start of
the call to register. The call will also be webcast over the Internet at</B><BR>
<FONT STYLE="color: Blue"><B><U>http://www.videonewswire.com/event.asp?id=95523</U></B></FONT><B>.</B>&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Our lead anti-infective candidate
SYN-004 for the prevention of <I>C. difficile (C. diff) </I>infections, is a second generation compound designed to address a broader
population than its predecessor, which successfully completed a proof-of-concept Phase II study in Europe,&rdquo; said Jeffrey
Riley, Synthetic Biologics&rsquo; CEO. &ldquo;Manufacturing of SYN-004 is underway, and with completion of that we will be able
to commence toxicology bridging studies, followed by the start of clinical trials in 2014.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;In addition, we are making excellent
progress in our collaboration with Intrexon for antibody programs, which currently covers treatment candidates for <I>Pertussis</I>
and <I>Acinetobacter</I> infections. We expect to initiate IND-enabling studies of our <I>Pertussis </I>candidate before year end,&rdquo;
said Mr. Riley.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Riley continued, &quot;In developing
and interlinking cutting edge cellular technologies for a broad range of applications as Intrexon does, an antibody discovery platform
has been created that is powered to yield novel molecular entities intended to treat diseases for which current therapies are inadequate.
Our collaboration with Intrexon is a prime example of how two innovative companies can work together to pursue significant medical
advances.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">&ldquo;The Company&rsquo;s
<I>C. diff </I>and <I>Acinetobacter</I> candidates may qualify for </FONT>expedited review programs at the FDA for the treatment
of serious conditions with unmet medical needs, such as are addressed by the GAIN Act. <FONT STYLE="color: black"> The expedited
</FONT>programs established by the<FONT STYLE="color: black"> FDA not only point to the urgency for new medications for devastating
diseases, but also potentially shorten the time to market,&rdquo; concluded Mr. Riley.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s core competencies in
anti-infectives have been strengthened with the recent appointment of industry veteran Lewis Barrett to the post of Senior Vice
President, Commercial Strategy. Mr. Barrett was formerly Assistant Vice President, Established Products at Pfizer and Vice President
Global Business Manager, Infectious Diseases at Wyeth Pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Operational Highlights</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>SYN-004 Product Candidate for Point-of-Care
Prevention for C. diff Infections </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This second generation candidate is believed to be the only product
under development to prevent, rather than treat<I>, C. diff</I> infections. Healthcare-acquired infections with <I>C. diff</I>
are potentially lethal and affect 1.1 million patients,<SUP>[1]</SUP> adding roughly $8.2 billion to U.S. hospital costs<SUP>[2]</SUP>
annually. SYN-004 is designed to be administered along with target IV antibiotics to prevent <I>C. diff</I>. In July 2013, the
SYN-004 manufacturing process was initiated with the evaluation of beta-lactamase protein expression in Fujifilm Diosynth Biotechnologies
UK Limited's pAVEway<SUP>TM</SUP> platform. Synthetic Biologics expects to initiate a clinical program for this second generation
candidate in 2014.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We believe SYN-004 is a breakthrough
candidate within a market where no approved prophylactic for <I>C. diff</I> currently exists,&rdquo; Mr. Riley noted. &ldquo;As
strange as it may seem, the only treatments available to patients are more antibiotics or fecal transplantation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Monoclonal Antibody (mAb) Programs
in Collaboration with Intrexon Corporation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
mAb product candidate for treatment of <I>Pertussis</I>, which is intended to neutralize the pertussis toxin, will undergo initial
preclinical testing in the third quarter and is expected to enter IND-enabling studies before year end. <I>Pertussis</I>, or whooping
cough, is responsible for 300,000 deaths annually worldwide<SUP>[3]</SUP> (primarily infants) and afflicts 41,000 people in the
U.S. each year<SUP>[4]</SUP>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
mAb for <I>Acinetobacter</I> infections is currently in the discovery stage. The urgency to develop a treatment against this deadly
pathogen remains high. Mortality rates as high as 43 percent have been reported<SUP>[5]</SUP>, and incidence of the disease is
reportedly increasing, especially among wounded military in field medical settings and natural disaster victims in emergency trauma
units.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Phase II Study of MS Candidate, Trimesta</I>&trade;<I>
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Topline results from a 164-patient relapsing-remitting MS Phase II trial at 15 centers are due
in the first half of 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In
                                                                                                          June 2013, Rhonda R.
                                                                                                          Voskuhl, M.D., was the
                                                                                                          keynote speaker at our
                                                                                                          investor day focused
                                                                                                          on MS. Dr. Voskuhl holds
                                                                                                          the titles of Professor,
                                                                                                          Department of Neurology,
                                                                                                          the Jack H. Skirball
                                                                                                          Chair in MS Research,
                                                                                                          and Director of the
                                                                                                          MS Program at UCLA School
                                                                                                          of Medicine, and is
                                                                                                          the lead investigator
                                                                                                          of the Phase II Trimesta&trade;
                                                                                                          clinical trial for relapsing-remitting
                                                                                                          MS. During the event,
                                                                                                          Dr. Voskuhl led an in-depth
                                                                                                          discussion about the
                                                                                                          MS space and the role
                                                                                                          of oral estriol (Trimesta&trade;)
                                                                                                          in the treatment of
                                                                                                          MS (the archived webcast
                                                                                                          of this event is available
                                                                                                          at <FONT STYLE="color: Blue"><U>www.syntheticbiologics.com</U></FONT>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
April 2013, we announced that U.S. Patent No. 8,372,826 was issued to the Regents of the University of California which includes
claims to the use of our drug candidate, Trimesta&trade; (oral estriol), in combination with glatiramer acetate injection (Copaxone&reg;).
Copaxone&reg; is the number one selling MS drug with approximately $4.2 billion in annual sales, marketed exclusively by Teva
Pharmaceutical Industries Ltd. Copaxone&reg; is expected to face generic competition as certain patent terms begin to expire in
2014.<SUP>[6]</SUP></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Upcoming Milestones</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Relapsing-remitting
Phase II MS clinical trial:</B></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Final patient final visit expected January 2014</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Top-line results expected 1H 2014</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>C. diff</I> Program:</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Initiation of cGMP manufacturing expected 3Q 2013</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Initiation of clinical trials expected 2H 2014</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Pertussis </I>Program:</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Initiation of preclinical program expected 3Q 2013</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Initiation of IND-enabling study expected 4Q 2013</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Acinetobacter</I> Program:</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Discovery stage in collaboration with Intrexon</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Three and Six Months Ended June 30,
2013 Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses were
$1.3 million and $2.4 million for the three and six months ended June 30, 2013, respectively, compared to $1.2 million and $2.6
million for the same periods in 2012. The decrease of 10% for the six month period ended June 30, 2013 is primarily the result
of decreased outside legal and consulting fees. Non-cash charges related to stock-based compensation were $299,000 and $652,000
for the three and six months ended June 30, 2013, respectively, compared to $287,000 and $786,000 for the same periods in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses were
$1.2 million and $2.3 million for the three and six months ended June 30, 2013, respectively, compared to $547,000 and $933,000
for the same periods in 2012. These increases of 120% and 149%, respectively, are primarily the result of additional employee costs
and increased program costs associated with our infectious disease programs. Non-cash charges related to stock-based compensation
were $109,000 and $212,000 for the three and six months ended June 30, 2013, respectively, compared to $113,000 and $122,000 for
the same periods in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other expense was $36,000 for the three
months ended June 30, 2013, compared to other income of $7,000 for the same period in 2012. Other expense was $24,000 for the six
months ended June 30, 2013, compared to other income of $12,000 for the same period in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash at June 30, 2013 was $6.9 million
compared to $10.0 million at December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics will hold a conference
call today, Wednesday, August<FONT STYLE="font-weight: normal"> 14, 2013, at 4:00 pm EDT</FONT>. During the call, Jeffrey Riley,
Synthetic Biologics&rsquo; Chief Executive Officer, will provide a brief update of the Company&rsquo;s MS clinical program and
its infectious disease pipeline, including its oral enzyme candidate for the prevention of<I> C. diff</I> infections and monoclonal
antibody candidates for the treatment of <I>Pertussis</I> and <I>Acinetobacter</I> infections. Evan Ballantyne, Synthetic Biologics&rsquo;
Chief Financial Officer, will review the Company&rsquo;s financial results for the second quarter ended June 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interested parties should call 1-800-860-2442
(U.S. toll free), 1-866-605-3852 (Canada), or +1 412-858-4600 (International), fifteen minutes before the start of the call to
register. Registered callers on the toll free line may ask to be placed in the queue for the Question &amp; Answer Session. The
call will also be webcast over the Internet at <FONT STYLE="color: Blue"><U>http://www.videonewswire.com/event.asp?id=95523</U></FONT>.
If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, <FONT STYLE="color: Blue"><U>http://www.videonewswire.com/event.asp?id=95523</U></FONT>
for 30 days after the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics (NYSE MKT: SYN) is
a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases.
The Company is developing an oral enzyme for the prevention of<I> C. difficile</I> infections, and a series of monoclonal antibody
therapies for the treatment of <I>Pertussis</I> and <I>Acinetobacter</I> infections. In addition, the Company is developing a
drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For
more information, please visit Synthetic Biologics' website at <FONT STYLE="color: Blue"><U>www.syntheticbiologics.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To download Synthetic Biologics&rsquo;
investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please
click on the following links to download the IRapp on your <FONT STYLE="color: Blue">iPhone and iPad</FONT> or your <FONT STYLE="color: Blue">Android
mobile device</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Copaxone&reg; is a registered trademark
of Teva Pharmaceutical Industries Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release includes forward-looking
statements on Synthetic Biologics&rsquo; current expectations and projections about future events. In some cases forward-looking
statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot;
&quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot;
and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties, many of which are difficult to predict and include statements regarding advancing our clinical programs,
the opportunities and our position in the infectious disease market, the anticipated contributions of Lewis Barrett, the anticipated
timing and results of our development efforts and the expected size of the future market for sales of therapies for C. difficile
infection, Pertussis and Acinetobacter. The forward-looking statements are subject to risks and uncertainties that could cause
actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could
cause actual results to differ materially from those reflected in Synthetic Biologics&rsquo; forward-looking statements include,
among others, a failure to receive the necessary regulatory approvals for commercialization of our therapeutics, a failure of our
clinical trials to be commenced or completed on time or to achieve desired results, a failure of our clinical trials to receive
anticipated funding, a failure of our monoclonal antibodies for the treatment of infectious diseases to be successfully developed
or commercialized, our inability to maintain our licensing agreements, or a failure by us or our strategic partners to successfully
commercialize products and other factors described in Synthetic Biologics&rsquo; report on Form 10-K for the year ended December
31, 2012 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and
Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new
information, future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Kris Maly</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vice President, Corporate Communication</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(734) 332-7800, Ext. 22</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>[1]</SUP></TD><TD STYLE="text-align: justify">This information is an estimate derived from the use
of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year
2012. &nbsp;IMS expressly reserves all rights, including rights of copying, distribution and republication.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>[2]</SUP></TD><TD STYLE="text-align: justify">Agency
                                                                                           for Healthcare Research and Quality.
                                                                                           Healthcare and Cost Utilization Project.
                                                                                           Statistical Brief #124. <I>Clostridium
                                                                                           difficile</I> Infections (CDI) in Hospital
                                                                                           Stays, 2009. January 2012. Available
                                                                                           at <FONT STYLE="color: Blue"><U>http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf</U></FONT>.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>[3]</SUP></TD><TD STYLE="text-align: justify">World
                                                                                           Health Organization. Pertussis: Immunization
                                                                                           surveillance, assessment and monitoring.<BR>
                                                                                           <FONT STYLE="color: Blue"><U>http://www.who.int/immunization_monitoring/diseases/pertussis_surveillance/en/</U></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>[4]</SUP></TD><TD STYLE="text-align: justify">Centers for Disease Control and Prevention. 2012 Provisional
Pertussis Surveillance Report. January 4, 2013.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>[5]</SUP></TD><TD STYLE="text-align: justify">Falagas, ME, Bliziotis, LA, and Siempos, II. Attributable
mortality of <I>Acinetobacter baumannii</I> infections in critically ill patients: a systematic review of matched cohort and case-control
studies. Critical Care 2006, 10:R48.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>[6]</SUP></TD><TD STYLE="text-align: justify">Teva Pharmaceutical Industries Ltd. Form 20-F filed with
the SEC for the year ended December 31, 2012.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Financial Tables to Follow -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;
</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Synthetic Biologics, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>(in thousands, except share and per share amounts)</I></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>(Unaudited)</I></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Condensed Consolidated Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Cash</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">6,877</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">9,954</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,880</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,509</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Note receivable, current</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">155</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">223</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Long-term note receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Deposits and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">37</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,627</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">13,423</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">229</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">395</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Stockholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,398</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,028</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,627</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">13,423</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Condensed Consolidated Statements of Operations</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the three months ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the six months ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs and Expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;General and administrative</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,258</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,176</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,380</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,644</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,203</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">547</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,321</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">933</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total operating costs and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,461</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,723</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,701</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,577</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss from Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,461</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,723</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,701</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,577</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income (Expense)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Other income (expense)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(46</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(45</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total other income (expense), net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(36</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Loss from Continuing Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,497</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,716</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,725</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,565</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Income (Loss) from Discontinued Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(156</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">493</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,497</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,872</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,725</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,072</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net Income (Loss) Per Share - Basic and Dilutive</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Continuing operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.06</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.05</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Discontinued operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.02</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Net Loss Per Share</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.05</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.11</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">44,654,414</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33,011,460</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">44,628,051</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,507,312</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!-`8H#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBN4\7
M^,_#G@32+C7_`!9K%AH>BVHC$E[>R/NDGDD\M+:WMHT:>ZGE8HL,-JMQ.[,1
MY`4;RTKNRZB;LKLZB0@(Q/3';&?U(%0/(@VG#$XQD*S`=EW%`P7))P6P#WZ8
M'P-XR_;>*7,NG^`?!8OLS&&UU7Q)=7EL;MQ(Z?N/#^G0_;]IV@XDU.&ZC)V7
M%E"RR+'F>'?C7^T/XC_MJ]/A_2$O(=,F?PQHC:"UAH>HZR_R+;^)=;@EU_Q%
MH>CPQG[0+FVTR=[RX2*RGN].\^*27GQE26%PF,QLL/5Q-/!X>5?V-"FZM6HX
M[PI4XWE5JNRM""<FNFHZ$8XC%X3#>VI89XNM'#K$5YJE0IN5K.M5E[E*G=ZS
MG[JU;:2;7Z"F9%8LS!`VU`3&1EW&`H<@*[,>%5&+YP`"V%-B'[YX*_+QN!#$
M`CJ&PV!VRHZXZ8K\7[GXC_\`!2WP3JT4&KZ)X>\0R7]_?7=A;+HFE:A9W5O(
MYG73;&_TU[.6UM;2W4+!!>7:744+;[V\N)Q(B]A8?MX?M+>`Y"GQ<_9G@N;*
M(G[1J?AC4-2T&6*'`/G&TOT\2V=U*7VQ?+J5C"6?=N0`J?YYI_28X`H8VM@<
M\R[BSAZMAJU2E4K9OPWF_L(.E)QG.-:&%G"C27(Y7E)*,==FC]E?@1QA6H4:
MV29IPAQ&JT*52E0R/B?*)XBLJD8J,71KXFA*M4O)*7+ISQDULS]>:*^%OAY_
MP4"^!OC#2M0U/Q7>:E\(O[(OM!TO4Q\1;1;#38M1\3_;5T6W@U[3YK[3&6[F
MTO4D26\>Q&RW$S*L;!F^S=(URRUJQM-3TR\T_5--OX%N+'4M+OK?4-/O(CD&
M2SO;-YK6[A)#;)HIB&Q@JK`K7[CP[Q)D7%N2X7B+AS,L/FV2XV4X87,,+[1X
M>M4I<OMJ4'.$&ZE%RBJL+<T'**DDVC\RSWA_.^&<PQ&5Y]E>,RO,,-/V=7#8
MFE::E92O"4'.G4BXM24J<Y1<7S)M:FY14'G<@<9(/'T[9!J0%QMW`9)P<<^G
MI^/Y5[2DG)QLTUW5D]M4WIU[GBJ<7'F335U%I:M-M+5+7KKY)CZ***HH***X
M'XC_`!)\'_"3P7XM^)'Q&\1Z/X-\`>!=!OO$WBWQ9KT\EKIFA:'I=M+=:CJ%
MTX1FF2"-(EA@MA)=7T\QM+.&6[C6&8`[@SQ@\D@?-\Q&%&QBKY)Z!2"6)&`H
M+$X&:/M$6<;B2,$X4L%!`(8E00$((P^=AY^;@X_BT_:S_P"#G7XI:QXBU3P_
M^Q;\)O"?@_P3:M):Z9\3OC18:CKWC?Q0D:#R]7TOP)I]Y8:%X-M1(["WTWQ!
MJ/B[5;N-$EOX-#N_,TH_`&G_`/!Q#_P4_MM5GU!_BU\,-466:`RZ'=_![P,^
MG1B$*9+-%TYK+6+=+A3^]:>]^V(K#RTC01NU<DNWY`?Z)8GC8A0221N&`2NT
M<%MX^3:#P<,><X!P:<'0_P`6!P03D`@]U8@!A[J3U'J*_DS_`&&O^#EC2_'O
MC'0_AG^V]\./"OPN&OWEII6G?'GX<7FMIX"TG5KJXM+;3(/B-X&UUM3U3PQH
MF^2XNM9\>:1XJU32M*@*W&N^'?#6AQ3:S'['_P`%9?\`@JW^WQ_P3N^.^@:)
MX1^''[.7C3]G[XLZ(=;^#_CWQ#X7\?7>KBZT.QTL>-?"?B.[T'XD:;I5YJVA
MW>IV&LV%S;6.D1:MX5\1:-=V<$UQI^LNB::W`_IH\U=Q4;B0`>%;!!.,AB`C
M8/4*Q(]*DK^=?_@CO_P6J\1?MZ_$;QU\"/V@_#'P\^'WQ@BT]O&?PG_X0&T\
M1Z7X=\;>%]'AM8O'/ARXM_$6N^(Y3XU\)O-!X@@2#48EUWPY=ZG/9::B>#-9
MU*[_`*(IY&C52BJS,X0*S8R2K$$<'(!`9^FV,.XR5"L@%:9%;82"_P#<4J7.
M>1\N<\]L@9[4K2HH+$@X[*03_,5_,/\`\%7_`/@O#XY_8\_:)M/V<OV8O"GP
MG^(/B'P;X>M[_P"-VO?$*T\5ZQIVA>*]::VN-'\!:+8>'/$_A81:IH^A3V.L
M>*+V:]U6".X\0Z3H*)9:G8:J!A?L;_\`!7?_`(*%_M)_LW?MN?M6>*OA7^SA
MX6^$W[*7P"^)7BWPUJ6F^$OB+&WQ"^.'A[P=>>,M!\&I/=?%2\$?AGP[HT%E
MJOCV2!(=6E3Q!X:T[3I=,EU.YNM-`/ZD_/CY(.X#&64J5`XRQ8-@`$X)SU!J
M4$$`@@@@$$'((/(((X((Y!'6OX2M._X.?OVXH;ZQN-1^"W[+^HZ?;7MI+J6G
M6'A_XDZ7?:AIPGMS>6-IJMU\3[FUTJ\OXGDM=.U.XM+NUL=2E@GO[.YLEE1?
M[0_V>OV@_AU^TY\'OAI\=?A+JIUOX=_%'P[;Z]X?OI8;BWOH'4SVFL:)JMK.
MB/8Z]X:UJUO=`U[3IBT]GJVF:G;XD%E/)&`>XLP7D_\`Z@.I^@[XSU%-\U.<
ML%P"QW$+A0"=Y!(*K@'YB`.#G%?,O[:GQC\2_L[_`+)/[2/QZ\&6.B:IXN^#
MGP4^(_Q)\-:;XEM[NZ\/7VM^$/#&H:WIUKK5MI][IM_/IL]S9I#=QV>H65RT
M$CB&YAEV2)_+Y^Q)_P`'!O[8G[1_[6O[.GP"\;?"_P#9PTGPA\7/B=H?@KQ)
MJ7A?PS\0[+Q#::9JD-Y--=:1<:A\2=2TZ#4(VM5\F2ZTV[@7>Y:!V"%`#^QU
M94;C.TD$@-@'`(YZD8.05R<D<@8!IV]/[R_]]#_&OX??BE_P<J?MP^"/BE\3
M_`VE_"?]E^ZTOP5\2OB'X.TRZU#PM\39-0N=,\)>,=8\.Z=<7\EO\4K>WDO9
MK/3HI;J2"VMX7N))6BABC*1IPW_$3U^W=_T2#]E3_P`)/XI?_/7H`_N[WI_>
M7_OH?XTUI4&<'<0`2%P3@G&>O0<D\\`9K^$;_B)Z_;N_Z)!^RI_X2?Q2_P#G
ML>XKL_AM_P`'*_[<7C+XD_#?P;J7PF_9?MM-\8?$/P/X3U*YL/"OQ-CO[?3O
M$GBK1M"OIK&2?XI7$$=W'::G-);2303QI.D;/%(@='`/[A?/B)(5@Y&,A"&(
MR,CC/<<C&<CD<4]75B0I!*XR,@D9SC(!)'0]<9QQ7\?G[>W_``7\_:__`&6_
MVPOV@/V>_`7PS_9VUKP;\*O&<7AWP]J?BWPW\0KWQ'=V+^'-,UEI-6N=+^(V
MDZ?/<M=7SJSVVG6B>5'%B/?O=_Z$?^"97[4'CW]LS]BGX.?M(_$[2/"NA>-O
MB(?'BZSI/@FTU6Q\,6@\*?$CQ?X,L/[-M=:U;7-2B^T:=X?M;J\^T:G<[[Z>
MY:'R;?R8(@#[S)`!)X`!)/H!R:C\U.N?EY._(V\9)^;.#@#)QGCGI4I&00>A
M&#VZ^XY'X5_%[^U9_P`'$W[9_P`#/VG?VA_@OX6^%O[-6I^&?A)\9/B1\.?#
MNI>(/#'Q&N-=O=&\'>)=9T33;S6+BP^)FGV4NI3P:;!<7CVEC9VK7+RF&UAB
MV1*`?V>B9&`9275L$,BLZG.,<H&]<Y.!CGI3]Z?WE_[Z'^-?SL?M2?\`!6C]
MH?X)_P#!*W]C_P#;B\+>"?@]J/Q5_:$\6>#-"\8^'M?T7Q;<^`],M/$7A'XB
MZ_?OX=T^R\8V.N6TRW?@W3XH3J.O:DBP75\'1Y&MWM_QJ_XB>_V[CS_PJ#]E
M3G_J4_BEG_U;'U_(TTF]D!_=YO3^\O\`WT/\::\J(C.6!"J6(!!)"C)P,C)P
M.!FOX1O^(GG]N_\`Z)!^RI_X2?Q2_P#GKT'_`(.>OV[N_P`(/V5/7_D4OBD>
M5&\?\U8Z@J"#V(![4M@/[N%FC8G##`SR2`#AG0X.><%#GV((ZT_>G]Y?^^A_
MC7\<O[5/_!P;^V+\#-7_`&?-/\*?#+]G34XOBQ^QG^RQ^T3XA?Q%X;^(=S+9
M>,_C=\,[+QCXJTS2&L/B1IRQ>'+#4KAK?0[:\2\U&"R1$OM2OI]T[_+W_$3U
M^W=_T2#]E3_PD_BE_P#/7II-NRWW_K[P/[N]Z?WE_P"^A_C1O3^\O_?0_P`:
M_A$_XB>OV[O^B0?LJ?\`A)_%+_Y[%!_X.>OV[P"?^%0?LJ#`SG_A$OBEQ_YE
MBAIIV8']W(E0LRYP5.#DC@XSR,Y7_@0'/'6E,B`@9SDX!`)7/H6`*J?]XBOY
M:?VOO^"VO[4?[/\`^QS_`,$XOVA/!_P]^!6I^,?VOOA[\3O%GQ%TKQ'H/CFY
M\-:!J'@B3X<1:7;^"K33_'NG:C865TOC+4/[035]3UJ5S:6'V:6V"W/VCV__
M`((Q?\%:?VB/^"BWQ:^-O@3XT^"?@]X5TGX;_#GPOXMT2Y^&>C>+]+U"[U'6
M/%-UHUS!JDOB/QCXFAFLH[:-9(8K:"V<3%C))(A*%`?T4;@%#'(!`//49QU^
MF>::\JQD!LY8$J!CYMHR0"2!D#G&1QD]`:^3/VP_VUO@'^PW\)+[XO?'WQ6N
MAZ*+M]'\,>'M.M+C4_%_C[Q3]BN]0M?"O@[08%\_4=4GM[-Y[FYG:UT?1M/5
M]7US4=/TI?M)_D2_:$_X.</VM/&^N:A;_L[?"WX8?`_P9'*T>EW'C6RN/BG\
M0KBWQ&PN=7NGO-'\#V,T\95CIFD:/KMK8N\D(\3:PR;H`#^YY;B)L;2Q#9P?
M+D`)#%2`2H!;()"YW,HW*"I!+UD5R0N<C.<J5((QP0P!Z,#TQ[U_GD>$_P#@
MX@_X*9:#JT-_K'C[X2>/+%+HSS:)XF^#_AFULI8GE20VBW?A)O#VK6UL@#)&
M+>[,RAV??)-@U_0U_P`$VO\`@OU\(_VO?%WAWX%_'GPC8?`+X_\`B:2+2_!%
MS::I?:I\*_BMKDP>632/#M_J5O'JO@7Q'>B)FT7PMXJO-1T[6I8I++0?&FL:
MA+:VDH!_1!14%O(\L9:151M\B[58L-JN0IR0K!BH!='1'C<LC("N3/0!1U.\
MM].L+S4;N9;>TTZWFO[N=L[8;2SC:YN9#@C(6".0G)P.ISC!_%SXF_$;Q)\:
M_'WVYGN([1;Y].\)Z2)'>'2-.22:$W"A"T7VVYA#7-]=K^^?>(/,:"*)!^K?
MQT>Y3X,_%$VF_P`\^!/$Z#R\[Q%)I%TER1CD;;9IFR""`,@BOR:^#UG#+XFN
MKHD?Z!I=U]C5`%6,37,5@D@4LV&BM'1LDYD;))0ME>BC34DY-NZT5OE_F)JZ
ML?;WP$_9\T/3],BU_5[2.Y\V-H;=TW"YU-HY0D]Q(X6/[+I,<L(@T^PM/L[.
M\4MU=O+'/'&OV'9Z=;:=;I::=91V%M'DI!:6\,$.XK@OLB"#S&XWNPW,1EB3
M5/PHL$/AKPY%;!5A&B:3L('.R2RA8$X^\TC[WD<[3O8D@L3735SR4924VGS1
MORM2DDK_`-U/E;WW33OKHK$J"3YHZ3T3DU&3Y4[\MI)QM>[O:]^NAG+$XR#'
MDXQDJPSQQDJV#ST./3ZU%<V:S)Y<ENDR2$JT<B"6$JRD,)%8<(0Q#9#Y/!'6
MM:BN:M@\/B:;I8FE#$0G=58UX0JJI&5N:#4XRY8-J_+&R^S;ET'&+@U*'+"<
M9*490IQARNZ>T;)[;VNKW3YDF?.7Q(_9I^$7Q2\-ZIX6\3^!--32]4O;35KH
MZ-;6VG2G5M/M]1M=/U`>3"+:::WAU;5`OG65T2UPLT@:0*M?FMKG[&'[2G[*
M=Y?>-OV/_B9J5SH"2MJ6H?#'6Q=:QH&I-$&N)EOO"$B/%,UT$:&2_P#"UY;:
MM(T@$5A`5-PG[;519`Z@')!4@CH&`'0].,G]`>1U];)<:\BPD<LR_#X6EE*E
M*7]EQPU%8./.TZDZ-*,8JA*3UJ3HN#J24'/F<8V^DR[BS-\M4J$JJS#+Z]3G
MQ.7X^'UNG54E%3Y:E5RQ%.T8^ZJ=6*5HW3Y8V_,_]GC_`(*(^%?'NO6WPO\`
MCGH<GP4^,$DRV,,>ISA?`?BB^8K"D?AS7[UPNE:C<3AH;/0-?_?SWCIIMKJ>
MKZ@PW_IA!/&PB(D4[@"I4L5?,8)*,W+J-P.[D8(R<\5\4?M6?L7_``T_:*\/
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M#XA_M'>`_#_C=[2680ZEI>B>%O&OC71?#=\(U9"M[XI\/:%K\-M(7\V?PU;M
M%`Y:22+^C&OD[]M+]D#X;_MP_L]?$']GGXH2W-EH?C&WTZ^T3Q#I]M;W.K^"
M/&GAZZ_M'POXST5;@HDMYI>H1PI?6,DL,&KZ*^HZ'-+;V^JW<S,#^!3_`((M
M^"OV0O'O[<OA?1?VS+CP0O@9?!/B.\^''A_XEZK9:5\/_%GQFCUCPO#X6\/>
M+#JMT-&U2WN-'G\1ZAHGAS4=7N+'Q%XDM+;3;K3=2!AMY?[YO%W[&/['OQ*\
M&Q^$/$_[,7P`\1>"IM*.GVNGCX5^!+:QLM/E`E1M`U/2-'MKK0@!*]S!>>'K
MNV:*Y16@O[%PS2?P-?M6_P#!%'_@H#^RWJ.L+=_!?5_CQ\-K87:VWQ.^"&G-
MXVT;4=-A0.T_B'P);SW/C_PKF$,^H1:EX=OM(M)D^SV>O:H0MR/CGX7_`+6O
M[7_[*FL#0?A7\?OCI\&-2T61'E\&VWBWQ+HNEV;VNS,%]\-_%KW?A^^MXF5/
M,T[5?#5Y;RXW3VKS>9*]W<VO+6ZOHOO_`$`_6C]IG_@WL_;=T/X__%G2OV9O
MA':>-OV>_P#A,+N]^$NN:W\8?AW8ZNW@O5,:S8Z/J(U[Q!I6OF]\.2W;>';6
M]U'3FGU&/28M3O-6OKV>>YG_`**M,_X)X?%']J?_`((]?#3]C?\`:^TZT\*?
MM'^!/`DND^$/$]YJNC>*YO`OC?X;ZWX@T+X.:]-XA\.7&I6.KV6H?#>#P[X8
M\<B"6>\O]`UCQ#;I&=0\FZ3\$_V5/^#E/]K7X9^(=)LOVJ?#/A3]I+X?M<10
MZSKN@Z+X;^%7Q<TJRDD@2ZU316\.:?HOPT\1WEM:K<2V_A?4/"_A%=;NC::>
MOB[PX#+=2?VJ_`KXX_#/]IWX1^`_CC\'?$<'BCX;_$+18M>\-ZPMK<VUR8FG
MN=/U+2=6TV^AM[S1/$&B:E9ZAH/B30K^*+5-%U>SO]+OX+:[MG4*5[Z]E\_/
M[[@?Y:FBZY\9OV/?VA[;6+$:C\-/C_\`LZ_$R:1H;V&07WA_QGX,UB>PU+3=
M1@/E'4]`U5[:[TS5H;I19>)-(U,Q6ICM-6BED_O&^*W_``6:^$>@_P#!+_3O
MV\/!0L9O'WQ#TJ?X=?#[X5:M?P7=WIO[24T5UINK^#]=LXKTW=QX?\!ZE#<^
M+=7E5+>]UGX?V>D7MA';W7B#3X)/S/\`^#D#_@G;]JM8O^"@?PFTDF]T2#0O
M!7[2>CZ5:>=+<:4D7]E>$/C/<1DR*UWHL-WI7@+QO>21SR2>'KKP?J4I2VT/
M6)HOY$)-6U$Z5:Z)+J=__8>FZKJFJV6C?;9VT[3]5U2STVPUK4+*Q2YDAM]1
MU:QTO2K1M1MA]HO(-/L(KUI)(VNWD#VOX3_"WXV?MJ_M(:'\.?"T]]X\^.'[
M0/Q&UFZU#Q!KL]U<B_\`$'B;4;OQ1XY^(/C"XM+:XDM].L8KO7/%_BF^2!IM
M+LH)-ML\$4`;^_?]I#]F/P!^Q[_P1F_:L_9W^&&G"#P9\.?V*OV@K`:K=*JZ
MMXM\1:E\//%&L^*/&>MK$SPOK/BGQ+?:OK5\H+)8FYM[.RD%DD-K8_#7_!O'
M_P`$[9/@;\')OVR_BIX>2W^+'Q_\-V,?POL]3LXH+[P1\!;N"QU33[ZWED>1
MK?6?BG=(/$EU<*BW)\&V?AR![G;J%TJ_K]_P5&_Y1N?MX_\`9I'Q_P#_`%6/
MB2@#_+YCMIKF9(+:UGNKAP[06]K;RW-Q*5MGBG,%O!')-*4MIY8[@PQN8[>Y
M*3;8[D+)_1G_`,&]?_!1@?L\_&\_LB?%+7D@^#'[0/B&UF^'M[=2C['X%^/&
MK/IFC:99RW,]Q#%9Z+\5;=[#P_=VL,5XT/C2R\(WT:P6^L:Y>-^6?_!,.UM;
M_P#X**_L6Z?>VUO>65_^T)X$L;ZSNX8KJSOK"[FFAO+&\M+A)(+BTNH79)X&
M01SXC^T+.L,*)[3_`,%=O^">^H?\$^/VI+W1O"=EJ2_L_?$ZXN_'/P!\1>;=
MQ'1(+*]A_MWX:_VLLKW,/B/X;:I<V=CHEPMR-4NO"\WA;7([JQNH[N2P`/[J
M/^"I,F__`()N?MWY9<K^RG\;UV]U/_"O]>!!(X.6PO'0J0>0<?P!?\$IR/\`
MAY5^Q,0,C_AH#PG@#`R19ZN,`'`!W#'.!GOCFOZ5?@M_P49C_;G_`."(_P"W
M5X6^(>LI=?M)?`+]D;XI>%OBN]S,!>^/-`/P[\2V'A/XQ6]N88`\GBJWT34+
M#Q9#;%XK+QGHVI,ZZ?9ZQI$+?S4?\$I01_P4H_8E!Z_\-!>%>H(.#;ZR1E6`
M*M@C<C#<C91OF4T`?W2:U_P11_X)D^*O$7B'Q1XA_95\/7^N^)M:U7Q'KFHR
M^,_B;`;_`%S7=0N=5UF_6"U\;0Q6[7^I7=S<S0H!"K,OD)&F0?YF/^#@W]B#
M]EO]C'5/V5H/V:?A-IGPN@^(-C\7I?&*Z=K/B76_[:N/#-Q\.H]`>;_A*==U
MA[<62:]JHD6TD@697AWH61F/]W]?QV_\'5__`"&/V(_^O'X\?^E7PEH`^+O^
M#?3]BW]F;]LWXB_M4:'^TM\+--^*.E_#[P5\'M5\'6FH:SXFT:/0]1\1ZW\1
M['7KF-_#6LZ+<W,^HKHEH[_:KB:U2)81;VT10>7_`%%:1_P1,_X)C>'==T/Q
M#H?[*_AVPU?P_J^D^(-)OT\:_%&0V6L:%JEGJFDWBQ3>-I8Y)+2]MH[E$D!@
MD:)4N8YHOD'X,?\`!JI_R5K]MO\`[)[\!/\`U)_B_7]H%`'^9;_P6)R?^"G?
M[9F`S?\`%SD.U59V./!?A_D(H+,0HP,`G'`K^T[_`(()_P#**;]E_H06^,>"
M"&!'_"]_B:."I(/IP>#D'!!%?Q9?\%B%+_\`!3W]LF-?O2?%*VB0]2))?"/A
MR.-ER"-ZR,C(2"%<*Q!`Q7SS\._C)^VIX6\':/H/PB^)'[5/A_X?6`O1H.D?
M#G7?B[IO@ZT%WJ5YJ&H?V18^'+C^RXA/JUYJ%U>-`J@ZA/>1DLT)(`/]5>O\
MLW_@HID_M]_MM'!P/VIOC>"P!V@M\0O$YV%A\H<KDM&2'"D;U`89T#^T'_P4
M<((_X7#^W!@@@Y\6?'I1COEC<*%&.K%E`&22`,CY$\5:CXEUGQ'K^M>-+WQ!
MJ7B_6=8U+4/$^H^*SJ4GB6^\07-S+>:S>Z[/J[/J,VKW5W>I+J3W;M*;G,;`
M-`S.`?TW_P#!0;_E7B_X)D_]E(^%_P#ZK;XZU^>'_!#_`/9J^"7[5O[<<7PH
M_:#\!V/Q&^'Y^#GCSQ&WAR^U/7-+@36]*FT.#3+]KWPWJ6C7I:TCDN0BF[19
M+@RM-%*I.[]#_P#@H/\`\J\/_!,G_LI'PP_]5M\=:_G6^`_Q1^/GP=\=GQ=^
MS=XO^(G@GXD'1]2TEM6^%T>JS^*5T*\CL)]3M2=(L;VXDL)G1&NY!&L:.BA@
MK*&JX*ZDKVVU^\#_`$+O^'&W_!*W_HT_PQ_X7/Q5_P#F\IDG_!#C_@E;&C/_
M`,,G^%OEQRWCOXJ*!D@<D^.R.^,8^<G9_%7\47_#?/\`P5W_`.CC/VT__`3Q
MY_\`,]7=_"S]N[_@K-J/Q3^%NFZQ^T-^V1<Z/J?Q-^'NF:M;7]GXY^P76EZE
MXQT6QU"UO_,\.-&+&ZL[B:WO&<!4MI97+Q[?,66FFT]P/[6_''_!(3_@G9\5
M;GPC=?$#]FO0/$%U\/OAI\/_`(.^$7F\7_$FV&B?#;X9:%'X>\">%H/L7C*U
M%U;^'M$CCT^+4+M)=0OEC\^]N9I2"OXZ?\%HO^"7?["?[+?_``3\^*7QD^`_
M[/VA?#_XE>'_`!E\'--TKQ59^)_'>JW-GI_B;XJ>$O#VMVRV>O>+-1TYUO\`
M2=0N;0%[66:-I_,CYRC_`-6\7RM(@5%5",*H"D;FD89"\;2I4@YR6+Y`-?B+
M_P`'$7_**WXV_P#90?V>_P#U>/@&A-IW0'\:O_!)SX*?#/\`:,_X**_LQ?!/
MXR^%;;QO\,?'NK?%:V\7>%+N]U/3H-8MO#W[/OQ>\8:3&U]H^H:7J4!L_$GA
MW1=1S:W:,ZV;(P"MFO[@E_X(:?\`!+!E+']DOPR,EOE_X3?XJ[1DG(`'CI<*
M#D`$;@."21FOXT?^"%W_`"EK_8P_[#OQS_\`65/CU7^DI']P?5O_`$(T-MN[
MW\OZ8'\77_!RK\*/`'P*^&/_``38^$'PN\/6_A+X?_#[2_VFO#?@_P`,VMUJ
M-_;Z/HEJ/V?IH+..]U>YO-1N?),F6FN[F:9V=AO(-<S_`,&LV#^TA^U<IP"?
M@EX#RV1D`>/KO:-O^T2P#$=1@9P<>V?\'6WW_P!@G_KM^U'_`.D_[/%?)7_!
MN1K>K^&O&G_!03Q'H$DL.N>'_P!D8:UHLT*O++'J^E:IXBO]-D2!6!FDBNX(
M7@52C[RZ!CYH*H#\ZO\`@K1^VGK/[;G[:'Q-\:P:S=7/PG^'>M:O\+/@;I*S
M_P#$LTOP=X:O_P"S]0\5VD,37%G]J^(GB*WN?%U]K"3W,MQI;:/IIA2'2(L?
MO_\`\$>?^"&OP2UOX&>`?VI_VQ/!=O\`$_QE\6/#VE>-?AM\)/$$E]#X#\#_
M``^\1V*ZCX7UGQ=H,#V\GB;QIXET:^CU[^SM?:_TKPI;:AING2:;<:U93ZC%
M_&EX9LK2\;PSIUQY<-A>7.@V$Y;+0P6MS<6=M(SAW+/%%$Y+HTFYT4HTP9C*
M/]=+P9I.F:'X8\/:1HJ01:1I7A[0-+TN&U5$M8]-T[2;6SL%MTC&U(5M(HDB
M0$JL21A<+525G;R`_.CX[?\`!'S_`()[?'KP-J'@S6OV9?AE\/+J73);/1O'
M/P9\-:7\,O&_AJZ$4L=CJMAJ?AJTM;74+FP++/);>([77M,U6=%75=.N;8M&
M?X/_`-IC_@G#^US^SE^T!\4_@QH7P2^/?Q-L/A]XM-KX2^*_PT^#7Q3U_P`-
M^*=$O+&Q\3>"_$VD^)?"GAJXTF+68M.O=!?5UTAVD\-^([?7(3//<:=9Y_T_
M7(".3D`*Q.`S'&#T5?F8^@7YB>!SBJ$*.2R)-*BCS3G,14NTI<K&`&,9MV;R
MWC=`-I1,NRM)4@?&'_!-WXP?%+XZ?L3?L_?$'XW>%_&/A+XOW'@J+P[\1]-\
M>^$]:\$^*+[Q7X-O;OPIJ'B?4_#NOV6G:A8S>,!H\7BEP+.&R:36)/L"BS6&
MON"H=QC'.7.<#)`+,0"%3(56XSGD8(QR<XFH`R=?TJUUW0]8T.^!:QUG3+_2
M+Q5&2UKJ=K+8W`/MY4[DGC`&>@-?C;X.T#6?!?QBN/`LUI=SZJFH:KX6FM;:
M)I+FX*PR7NFWEJDD:#R98;2.\2<J(Y[-GFBS$F^OVG(R"/7CGT/7].W?IQUK
MPGQE\+]`;XC^%?C-).EEJ'@?3=??78_*4P:WI\V@:K86$\X)"17FC_:IYH;L
M`R&,+"S*B1LLU*ZPU*K5E*<(0ISG-Q496C&+DV^?W8JRLYOX%K?0B?*HN4W*
M,8-3DXMW2BT]>75Q[JSNNCV+OPA\0/=Z(GAO4HYK/6_#V(9;.Z@EM;AK&7]]
M:NL4V')A,C02X4I$HB!8;U)]G4GIGKR,G)[<?_6P#^M?B/\``[]L;XBZE:^9
M>ZW8:UKNGM<RZA8>(H+>]$MI>.;J2ZTJ_"VVK6MM,JB%X%N;JUCF7S$MK:W,
M"5^E?P5^/"_%:35+*;PQ>:3J&D0QOJ,\>H6%YID,DWF&"$[Y+358GN$5G1VT
MZ2S`5_\`2T(4/^$\$^/_``/QOG/]@4J^.RW/IXK%X2G@,71C[#%5L+5E3YJ.
M)H.K32G&%[1G&/7=MG/A,QPF8)RPTX\UVW3U35DKVULHK7?6Z>FY](#D"BHD
MD!0$J5]N_)//7D8P0<D'((XP:>&!Z>F?UQ7[JI*+4)-1GRJ\=;7TNHR>DM=-
M'?NM&=C36_\`G\].FN^PZF>6G]T<=/;/7\Z?15[._6S5_)VO^2^X76_7OUUW
MU\R!U1G&X#*`%3GY@0#CG@@<D=3G)!ZU^9__``4#_9S^&'B3X(_$[XJW?A3Q
M*VI>!_#VH^+M='P\L+&^UVZT/0HI;[Q#K$7A*[DLK3Q1?Z+HB7VJG2-,O;+Q
M!XBL+2[TK3I;_4[JTTZY_2Z9L/\`<)^0$-P!D$X4'U/X?AU')>+M;\-:)X>U
M2]\::EI6B^&V@73]6O\`6]0LM-TN.'59TTR."]O+R:&UMH[Z:ZCM%EN98H1)
M.@E=5)-;87'8W+*L\7E\Y4<1!-JI*HU'2*?*[2UI2:2G!VBU=-,]CA_,\3E.
M<8+,,#*2E2Q-&%:C2:A5Q4%4A*IAX133K.K#FIJ,N9-RM;6Z_%?_`()D?M7_
M``3\-^'O@A^SZ_QET;XB^-_VD;WX^>+OAMJOAWQ1/XC\/V.E?!2T^&@B\$7=
MIJ]XGB/P7KFL>&O$6I>)_#?A#6-)TJZ.D^$_%(>T4):7VH?NM:%C;Q;]^X+M
M)D8-(=I*AG90H9V`#,0H!8G'&"?\QWQZFH_LO?M::E\0/A;,@UKX(_&W6-?\
M%ZIIQC,=VWPU\;ZC/H"QWRV[1W-MJ5KIT.E73R0R^?IL\^GWD%S'+/&O^EE\
M-O&FD_$3X>>!OB#H,B3Z'XZ\'^&O&6CSQL7CFTSQ3HUEKFGRQN50R)+;7\3Q
MR;%WJRML7.!\;PYQA6XJQ6=?7(TH8[`XZ=*LJ,7"G)-)<\4TE+F:O=7LK+1N
M3E_4OTL/H_8?P<QO!/%&49AC<UR#Q'RS'YE0K9EA?J>,P&,I8FGC*67NC!NG
M*E')\SRR*JO][/$8;$3DHQJ0A'N*_GV_X+:?\%0OVK_^"<7BK]G:'X#>#/@7
MXC\'?%S0OB9)XCU'XN^#OB)XEO;+Q)X)N?"#V%EHMSX-^*OPZLK2UN=*\0W5
MU=V]W::U>R&S\Z%[6!)`_P#00#D9QCVKX-_X*)?L$_#O_@H;^SUK/P4\<:@W
MA;7;#5+/QC\+?B)96;:AJ/@#X@:5;W5K9ZO)IOVJRAU[0=4L+RZT/Q)X=NKF
M**]TNZ>\L+G3?$EAH&N:+]8?R$?FK_P18_X+!_$?_@H'XT^,GPH_:/LO@IX(
M^)_A/3/#?BOX8:-\+/#_`(O\)6WC+PE/_;%GXS0VWC;XF?$B[U/5/"]Y#X?U
M"=+"?0I6TG7(KQ=.NTL=7EL/VN^,7[.WP$^/FDR:%\;/@S\,/BSI?V>:".W\
M?^"O#_BF>R%TIBF?3K[5-.O-2TF[D3;Y%]I5Q:7L,L0DBG1T1E_SE?V@/^"9
MG_!0G]A[QS%K.L?"+XD/'X/O4U;PE\>/V>[?Q9XP\*VUY8K,]IK^F^*/!MI;
M^)?"VJ0F*29=,\6:=X0UJWA625+:2U$N^P/^"EW_``5:FT<>!(OVH_VHGMT1
M1):PQ7\OBTL=I2%?$MEX>3QRH+/@M%JDD#@-;FVM%1H4`.[_`."TW[)7P&_8
MQ_;7OOA=^SIJ<\/@_6?ASX5^)6I^!;C6VUR3X5^*]>UCQA9'P=;ZK*UQJT>F
MW>FZ+HOB_3K#6[J;5M*M-;TY5NIM.DL8Q_23_P`&ONH^*+K]AOXNV&K&Y/A?
M2/VG/%UMX&\X,(5TRX\#?#Z]UF.T!9HXXD\13ZEOA@6.*.4O\@=GK^:#]F3_
M`()/?\%!OVX_B(FLW/PV^('@KP[XBU==8\8_M#?M!67B#PWI<RW<T+7FM6,O
MBN&+Q9\1M;GCFE;3XO#5EJFF+?`Q:I>6%LLZ#_0'_8S_`&5/AQ^Q7^SQ\/OV
M=?A>DL_A_P`$:67U+Q#>QB+6?&WB[59YK[Q7XUUQ/,N&2_\`$6KR3W4=J+NY
MM]*TX6.B:>T>F:79Q*`:?[8NGV-_^R3^U';7]I;WMM/^SO\`&E9[:\B2YMYD
M'PW\2D)+!,'BD0'#!'0J&"MC<JD?Y6_PZMK:^\7_``_LKRW@N[._\8>!;.^L
M[F&.:UO;.[\0:2+JUN[:16AN+:Y6:6.>"9'BEBD:&16B.RO]6/\`:ETG5=?_
M`&8_VC-"T'2]1UO7-:^!'Q>TG1M%T>QNM3U;5]5U+X?^(;/3M+TO3;**>]U#
M4;^\FAM+*QM()KJ[N98H+>*261$/^:3\._V%?VX+'QC\.[R]_8R_:PL[.S\9
M>`[J\O;O]G/XP6]G9VD&MZ%<7=Y<WDG@Y;:WM+*+S)+RXFDCA@C@FDDD")D@
M'^I!:Z?8V=M;6EI9VUI:VEO#:6EK:PQV]O:6D$4<,-I:PQ*D=M:Q0Q1Q1VT*
MI"L:A`FW(/P[_P`%1O\`E&Y^WC_V:1\?_P#U6/B2ONN)PZ`A67H,-PP^4'!'
M4$9VD,`P(((!XKXM_P""D?AOQ'XQ_P""?G[:OA+P?X?UOQ7XK\3_`++WQOT'
MPWX8\-Z7>:WX@U_6]5^'?B"RTW2-&TC3XI[[4M1OKN:*WM;.TAEGGE=4C1F.
M*`/\\[_@EQ_RD@_8C_[.-^'OTYNI,<U_H`?\%(_V'/"G_!0#]F'QC\%=9CL]
M-\:V!N/&'P8\97:.G_"'_%/1].U"'P[>WEU%;7$Z>&]:%Q=^&?&-I!!/)<^&
M-7GN;+;JEI83P?Q'_P#!-W]C?]L#P5^WW^Q[XO\`&O[*'[2G@[PEX;^/_@75
MO$7BKQ3\#?B9H'AK0=,L[H&[U'6/$&J>&;71M.LK4.OVNXNK^-+5FB68J9X/
M,_T<)8S+;-$I3+Q;5+J'0$K@,R9^=1U*AE+8P'0D.`#_`">+#Q'\:?V6/'WQ
MJ^'S?;?`GC:[\(_&#]F3XV>$-4B\^WNM!\7:5K7P_P#'?AG7K:&>&VOEL[WR
M=>\/:N'E-KXFTKPYKBQ7EI#/-<?2?_!*4@_\%*?V)BOF[/\`AH/PKL,ZE9C'
M]GUCRFF5B669H]C2A\2"0MYH$F\#^C'_`(.#O^"6_B_XFZEX?_;6_9P^'^O>
M,OB/-)I/@CX[>`?A[X;UOQ5XK\666VST+P!\4]&\.Z%!=:GJ6K>$K<VWA+QT
M]O9WIO/"*Z)JT=A;?V!>^=^+G_!,O]C;]KWP/_P4%_8\\7>,_P!D_P#:5\&^
M$/#?QP\+:IK_`(G\4_`KXGZ%X<\/Z3;Q:K;27^MZ[J/A6VTK3[.&1HXYM3NK
MJ.PE=S.MR8-THJ33M:R[Z>GW@?Z-M?QV_P#!U?\`\AC]B/\`Z\?CQ_Z5?"6O
M[$J_E#_X.8/@/\<_C;K/['P^#'P4^+GQ=7PU8?&K_A(9/AA\./%_CZ/0FU2;
MX:2::FLGPKI&JG36O1IMU]F^UB/SO+9HP55V60/GO_@U4_Y*U^VW_P!D]^`G
M_J3_`!?K^T"OY&O^#:#]G_X^?!3XH?M@7OQG^!OQ@^$-EXE\!_!.V\/7GQ/^
M''B[P);:Y=:5XB^*,^I6FDR^)])TQ=0N;"'4;.2\@MO,DMDGB:55#BOZY:`/
M\R[_`(+$$C_@IY^V65)4CXGQ$%25((\&^'R""""/SYZ'BO[3/^""*JO_``2F
M_9?"JJC=\8N%4+G'QV^)BC.`,X551<]$54&%50/Y.O\`@JW^R#^UIX__`."C
M'[6?C'P)^RW^T9XV\(>(?B4EQH?BOPC\$?B7XD\.:Q9KX2T2WDO]+UG2/#-W
M8:E8Q7$$MO)=6,]Q#Y\;1H[L#7]=_P#P1(\"^./AI_P3._9R\$?$CP9XK^'W
MC31&^*W]M>$/&WA_5?"WB;2/[1^-/Q$U2P&HZ)K5K9:C:&\TV]M+V`36Z>9;
MW$;C.2``?JW7^69_P43`7]OK]MA5`51^U/\`'`A5&U,GXA^)1G:N%R%557CY
M44(N%`%?ZF9(`))``&23P`!U)/8"O\U_]O3]C/\`;#\6_MN_M>^*?"G[)O[2
M_B;PSXF_:3^,FM^'_$7A_P"!7Q.UC0=:T74?&_B"_P!,U73-7T_PS/I][8:E
M;3QM9W%O<2)*6`X!4L`?IE_P4&_Y5XO^"9/_`&4CX7_^JV^.M?,G_!ML#_P\
MEA.#M'P$^*/7.U7>\\+2+@'Y5=F>\*X`8J)E'R(P7[Z_;H_9Z_:!\5_\$'_^
M"=?PI\*?`GXS>)_BEX0^('P[N_%GPU\/?"[QUK/C_P`+VVG^`/C/97\_B+P;
MIN@W7B/18;&YU*QAO)=1TVWCMWNH-[8EC+?SEZ=^Q#^WWHURMYHW['?[96CW
M:6[6ZW>C_L^_'+2;SRI7\R:!KK3?#%K</`SD_*9L./E=-H`H`_U0Z0@$8/3@
M]QR#D'(YX(S7^6W_`,,F?\%)/^C8_P!O'_PT/[2'_P`J:5?V3/\`@I'OC+_L
MQ_MWE5EB8[OA!^TF0-DBMNVQZ.[NR$;EB56:5@(P#NH`_P!1^)(8P8X0JA>J
MJV<$EB2PR3N9MQ9C\SMDL20:_$/_`(.(O^45WQM_[*#^SW^GQQ\`YKZA_P""
M1?AKX@>#?^"<O[*OA?XI>'?&7A3Q]H_@#4;?Q+X>^(&G:WI'C'2[U_&_BV:*
MW\0:9XDCBUZRU%K*2TFDAU15N5BEAW(J[<^'_P#!>/X>_$'XJ_\`!-7XP^"?
MA=X#\:?$KQEJ7CGX&7&F^$O`'A?6O&/B;4(=+^,7@W4=2EL=!\/V=_JEW'I]
MA97%[>M!;.+>UB>:3"J:`/X^/^"%P)_X*U_L8X'37?CF3[#_`(94^/7-?Z2D
M?W!]6_\`0C7^?=_P1B_9+_:O^&?_``5!_9*\=?$G]EW]HSX>>"=`UCXR-KGC
M'QU\$?B3X1\+:.NJ?LU_&C0M.;5/$'B#PWI^E6`OM7U73]-M?M-U&;B]O+>W
MBW22JI_T$(CE`<$'DD'JI/S%2.Q7.".H((-`'\@/_!UMR_[!1'($W[4>2.0/
MW'[.XY/09)&/6O"O^#7"SM;[]H?]KFTO8([FTN_@3X&L;JVG59+:ZL[OQWJ4
M5Y;SQ,"LB20GRRK`JZRR(<@\?9/_``<Q_`CXY?&V/]B?_A2WP7^+/Q@;PW/^
MT<?$47PL^'?BWX@S:"FKQ?`@:1+K4/A/2=6ETR'5#I&I#3Y;Q(DNS97*PLQA
MD">/?\&V7[/'[0?P6^/_`.TYJGQE^`WQH^$6FZW\'O!%CHE_\4/A=XV\`6>L
MWUKXXN[BZLM)N/%>BZ5%J-W;6[+/<06C2R0PNDC@*V0`?S)_M8?LX^(_V2?V
MB?C+^S?XL2]BO?A/XQU71=+O[II+>]UWP46DUCP/XICN/+M5*Z_X+OM'U5+V
M"/[.U]>!)(UMM'N!-_H0?\$AOV^_`?[<'[*W@+_BI-+_`.%\?"KP?X;\#_'#
MP3Y\-OJMKXB\/62Z&OCK3=+,LD\O@[Q\E@FOZ-J4#2V]O->7.A7;0:EIEQ"?
M+?\`@K=_P2%\(?\`!1+PO9?$'P+J^C_#G]J'P1HKZ1X2\<:C#?3>'?'/A:)K
M^^M/A_X\M[*4O;6EMJ=]+=>'?%UE:WVJ^&YKK58DM;O3M8NK:#^)/XJ_L6_M
M\?L0^/3JGB_X+_';X1^)M`GNX=$^*WP\C\37_AZYCNIRMS<^'OB_\.[F_P!$
MOK74HY8A=VNHZK;ZFEM+90:OHVC7$D!<`_U`=?US1/#6@ZUXC\2:QI'A_P`.
MZ#I>HZOKNO:_J%II6A:+I&F6LUWJ>J:SJE_-;V.G:7IUI!-<ZA>WD\-M:6T,
MTUQ+''&[#_.L_P""@?\`P5J_:6^,?[87QK\;_LW?M/?'OX8_`@>(+?PK\+O#
M?P]^*WC?P1HFI>%O`^@Z=X>/C!=#TK6--M[>?QGKJ:[XH+W%I:W"0:A96UVC
MMI_GS_$7C+XQ?MU_M/VMC\/?&GQ$_:K^/%BUW9VVG^`]8U#XE>.[6XU&*6-K
M)3X>==1@FNXG5#IL=]92O'*L8TVXM[R1)C^U'_!,'_@WZ^,/Q9\<>%_BO^W#
MX.O?A/\``O09M-UZ'X(^(]UE\3OBS+;F22WT;Q;HD$QN_A_X.:YRWB"+6)+/
MQM?0!--T[3="-ZVN60!_2_\`\$>]/^.2_P#!//X`^*OVAO'_`(^^)7Q0^)FE
M:Q\4KKQ#\3/$6L^*O%G_``C'CS7-2U[X?:?=ZMK]S>ZCY$/@R\T"[M89YV%C
M;W:6T>V*%$3]0:IV%G#86=O96]O;6EM:QK!;6EFGE6EK;Q#9!;6T("I#!;PA
M(HHHDCB14`BBB3;&MR@`KGO$FC67B+1]6T'46G6QUG2KW2KUK65X+K[)J-O+
M:7*P318D@E:&9A'.AWQ.`Z89<CH:*RKT88BC4HU%&4*L'"<)KFA.,E:4*D;K
MGIR5U.-US)M70FDU*+VDG%ZV=GO9]'YGXY_'_P#X)]/X;L;'QQ^R^;W3-:\*
MV<$5]X)N-0>1M?@LDE-Q?Z5JM\[7+:[=1&.+5-&U&YETS6[=4%D;*]4I-\=_
M#OX\ZE9>(Q:_:M2^&_Q-T&X>TO-/>*XTZY:^C9#<V2&]2"X<2.(5O]$OUCMV
MW+`%O(H83!_2;(/D?`7)&#NR`1[D`GIT/:OD/]H_]C3X/_M,6AG\6:3+H_C&
MWMS!I?C[PZ\5CXDL558Q;Q7A\LV>OZ=$8\#3]5AF$$9N/[.EL9[B2:OY;\2/
MHYX/,,=2XG\.ZU/AG/<`Y5Z6"PT_J^#J57K.5+E:6']I.\WI.#FY/W;GRF/R
M*K0E'%9)-X?$1U=!ZTJMM;.5TJ;;M&_*XV=W9K7R[X7?MPZ'=0PZ-\5;4>'M
M14M"OB/3+6ZET>>1%"M)?V2_:K_3)I9@Y,EM#J&G@[FE>SB4X^[?#7B31/%6
MG0:SX>U?3];TJY5S;ZAIEU!>6DRJ47"S02RKYD1#),C>4ZR`J8EQ7\[GQ7_9
M1_:X_9W^URV6AS_M#_#6R#"'5_!MI=3>,=,LLML%[X:59M9C>*"&-Y3I,6LZ
M8H8Q?;;*U0I;?._@[]IO3="U6:Y\/>,O$/PO\31NJ:A;W]S/X7NK>XC'ER0:
MM=M)%HR21NHR->,!0`1F%V88^2R'QD\3?#V5/(O$GA/&9OA\*E3P^98>C]4Q
M53V7+3]K2JR6(HXV+LYJK4J89U8MSO%R4'X<^,L=E514\ZP56DN9QDYMPG/E
MT<J"5.<:\'9.,N:'-'WVU<_K.R/4<]/>DR/4?G7\^WAC_@H/\>=$M[9'\2>%
M?'FG@0K#<ZMH=O>2S6X550'5O#\WA^%VG0!A>2?VA%/DRQR/NWGN;C_@J#\3
M[>-7F^%_@RX\G#2W,=WKZEX5(:41P$W$;NR;DAW3$M,\:JA)`K]=R[Z17A[C
MH+VSS?`UVJ<8X7$8*G.M4JU&DJ5)4,35C)Q;2G*;II)Q:3NU'HAXF<*;U\76
MP]I0@U/#RE+VE32$>6+>C=TY725M5J?M]?3Q6[H998XS,\5O"LDB1^;.^XI%
M$9&`DED"G;&H+84GH:^%OV\?VDO@3\!/@;XIL/CGI,'CC1_B3H^H>#H_A1"E
MI<:QXZT?7(WT[Q!_H5Z9TMM)TW2KBYO-2U6YA^Q6(CMX8IWU.ZL(3^?G_!0+
M]HOQS<_#W]G7POXDN++P1X^U2#2/CEXGL?#]U<P)X4U"RN?M/@&T@N=29+M]
M4TZYCN;C48IA`T%Y:K<1QSC[)$WX5_'SXKZAXINM:U[4=7UGQWXZUA/)OO%G
MB"]FU7RXRDR`174^TW4T$I9;'2[5+:T*ND4UC#-BW7_0/PD\!\1XAY/E/%F8
MXN-#AW'M>UR]4ZL<SG0NFZ52<5.EA/;T[J5:3G[&#3:NY./\<^-GTYWX=<=9
MGX<<!\,5\PXXP%7A_P#L[B'&8E1R;`5L51EF%:K['#T_KL<3A.7#4XQC4I7K
M5U5=:G[%*I\Z?'K]C;XNZ+\=/$/PE^%?@#XC_&;2T@T_Q)\.O%OA/P;K_B:S
M\<?#KQKIA\5_#[QG-?Z593VMHVJ>'9[./6#>)$;36K#5K&XDCFEM'/\`;[_P
M3YO/%5K^R!\`O"'C7X<?$;X7^*?AI\,?`7PTUKPS\3]'MM&U]KSP7X4T30VU
M&S@L=2U6.70;LVV-+N;B:WN]D#6]W86K1EC_`#P?\$I/V8?VY?V@=<^&^K_$
MCXU?'CP#^PW\%M9BU[P]\/H?%WBCP/I/QAU6WU34/$FG^&?#1TQ-)U+6_A_:
M>+&^V^-=6O;V\TN_ABD\&Z/]H$NJOI']?-LK+"F]@[DNS,,X.]V;'S,Y&`0N
M`Q08P@"!0/YSS3PEROPKXNS[`9;Q+1XC5;$8J\L))U,/@*57%1K4,%7JN4O:
M8[#4H0IU>3W8<THW;V_URXQ^G-QM],#PF\,L/QGP!3X5Q'".78+ESK%XO'5<
MVXAS=Y+@<LSO-8X7%)1PF68ZO@J-?#T.>K)2A%PK.+ES+&Y9L$\;<]?IU]^M
M345^*G_!;\Z:_P`&_P!D*QUWP_XQ\9^&-:_X*#?L_P"C>+O`?P]O-7M?&7Q`
M\+WW@_XO1ZOX)T.'0M:\/ZKJU[KMN6@@T2UU:T;4'/E*6=B&H_$^BOJTDF^]
MDE?YVN?M(MO$I)0%7*JI=3AR%\PJ&8<N`TLC@/N&]BY!8YJ%-.L8YWN4L[5;
MF1M\EPMM;K/)(``)))EB$CN`!\S,3P.P%?S8_`"Y^%?PX_X*5_LS^&_V?_@K
M^US^P]X'\<_#?X\V'Q2\+?M1K\7=&^'_`.U!XBL?#WAR]^''@'X1Z3XT^('Q
M+\%7?Q.\#0VGBCQOJMQ#J'@Z_A\*0301R:]/NTZW_I2M2#&2&W`N3NQC<S`,
M[`9.%9R6"\%,E"`5(``]K>-G$C`EQCY\X;"J0%W##!027V@A=Y+XR<T](UC+
M;=V&Y(+%N<DDY8DY)/.2>@QBGU%(&+Q'&4!(;IU)4H>3T#`<!2V[:0R@-N`)
M",@C)&01D$@C(QD$<@^A'(/--,8(P2_7/WV'\1;&`0"HSC:01MPI!%?F%_P1
MKU"^U7_@FE^RGJ6IWE[J=[=>&/&/F7^HW=Q>W<T2?$_QQ#;&2XO+F[NI!'#'
M!!$)[F62.*-8P5C1$3]0*`&H@08'J23@`EB<EC@#))ZG&3WH=`X`)88(.58J
MW!SPPP0#T.",J2IX)%.K\>/VS;&^_:0_;8_9=_81\3>)?%'A?]G[Q%\(/C'^
MT=\=?#WA/Q-K'@_4_CI8^#-8\.>"?"'P@U'Q1X>N](\2VW@)-5\0:IXG^(.B
M:/J5M/XEL/['T>_*:6UZ)0#]@'MXY!M?>R[=A5G9E90C)AU8LK_>+,7#%V",
M^[RTVSC@`>E?AOXO^!O@;_@G9^UU^Q+J?[)\>I?#/X2_M1?%SQ1^SS\?/V?K
M;Q7XFUOX;>*[N_\`AEXF\7_#WXK^&_#/B74/$D7@?QYX*U[PU%%K^J>&#H:>
M,?#&JW&D>(7EEDMKZOW%C(:.-@0P**0P*D,"H((*DJ01R"I*GJ#C%``T:N03
MD%00"I*D;L9Y4@]AQG![@TTP@D'?)\K;@-YV]%&"OW2/E!`(.TDE-I)-2U7O
M`#:70/0VTX/('!B;/)(`^I(`ZYH`L5$T*.Q9MQR8R5W,$+1-N1B@.TL"%RQ!
M)"(I.%`K\JO^")^JWVK?\$R/V6=4U;4K[5]0N=#^)S7.HW]W>:G=W)7XY?$R
M)6GOKN>\N)G2.)(A'+=3BTCB6%?(B5%?]6%8.,C/IR,<]QZ''J"1Z$T`-$:A
MM^7)QC!=BO15R$)V*<+U50?F;^\V9**J3#_2(@1N5QM7`P492S,2XY^==I3&
M"CQ!@<L"`"80H",9`#;L#`!.X.,@`9`;+#/\3NW4Y#U0*68%B6QDLQ/W1@``
MG"CJ<*!DDDY)K^?C]C;]E;X-_P#!2#X3Z]^VW^V7HNO?&#QS\:_B7\:D\#Z'
MKGC[X@>'_#W[./PP\`?%;Q;\.O`GP[^&'AKPWXKT+2?"7B70=.\%KKOC#X@6
M=G:>,+OQ1>72WFH7@M-]I]F_\$QO%?CJ#0/VJ?V=?&WC?7OB?:_L=?M5^+_V
M?/AY\1?%NI3:YXR\1?"J#P/\/_B1X"T[QIXDN2;SQ/XK\$Z/\0E\"ZWXAOA]
MNU:[\.-=7;/,[-0!^G9`((/((((]CP:C,*D("6.P8&6+$K\H*L6R6#!<-N))
M!.3DYJ6B@"$0("2-P)(+8(4LP).YB@4L3D@DGE20<@FG[!_>?_OLU^5W_!1[
M6O%_C3Q_^QC^QUX;\;>)_A=X6_:_^,WBS1/C-XZ\&:O<>%?%MY\)?A%\-]5^
M(_B;X:>%_&%@L6L>%-8^*$UII>@2>(/#U_IOB"#1[35;&RU!([F6VF^-[_X=
M_L3?L>_M>_`33_V>8?VB?V/_`!=8_'+P#\#_`(B0:9\"OVHO%W[+G[4-K\5E
MM-`\)_#'Q#\0O%Q/P>NO%2^)-6TW4/!_Q;L]>O?$&A>)-&UJRO&U5;">QM@#
M^AG8/[S_`/?9H,8/&Y_P=AQWYSD9Z9&".H(.#4%I'Y:.F5P)"%50!Y:!5"H0
M`!\H'7`8C!?+EC5J@!B1K'G:.6QDD[F(`P`6.6;')RQ)+,Q)RQJ-K=';>2X;
M>')#8.0H7:"02J'`8JA4%QN/);*3(S/#TV!SN^Z3R.A5U8,K+N1L%67=N7.*
M_,G_`()>WE]?^"/VNC?7E]>/9_\`!1S]M6PMS?7EU>O;65C\5)H;6QMY+NXN
MFBLK:)`D%O!);P1E04MQE]X!^G#PK(`&9\!@V-P(.&#;65@5*G&"".A.,'!$
MB($7:N<98\DDY9BQY.3@$X`Z*`%&``*=10!`MNBMN5I`<`$;SS@.,L3\S'#X
M^9B`%0*!M%#VZ2$EFD(*["-Y'][#`XW*XW':ZLK#C!X&/RI_X*.Z[XN\9>/?
MV)/V.=!\6>)_ASX1_;"^._C+0_C1XP\%ZW?^$O%6J_![X._"SQ/\4/$WPI\-
M>+-'N+;7O#6L?%2YT_2=`O=8T'4-,UF'PU9^+_L6H6D<\DE6?#G_``3K^"'[
M.'QI^"WQ:_9<\6']EE+#Q/J/A/XJ?#.'Q/XTU[X>?M.>$]9T2^T[3O"NN^'/
M%WCHZ;'\4-&UE;3Q'X8\>:9::IXM>ZL;V+44UFW?RK0`_5-E##;D@''W25/!
MSP1R/3((([$'FH4MXXP0FX`YR-Q(;)).Y3E79LD,[AI''WG.!A\1+11,226C
M0DL%#$E0<L%`4'U"@*#D`8J2@"K#96MMO%M!#;"0YD^S0Q0>8P^Z[F)%+,HX
M4L3P2""#BI(X(X23&"H(`VY)4`?="@YV*F2$C3;&@)"(,T7)D%O.8GBCE$,I
MBDGSY*2!&*/-CGRE;#28YV`U_(CJ_P`(O!'PH^%WC>?]O?X*_MK?!C]LNQ\1
M^,_&,O\`P5S^&.F?$'X\_"?PUJ=_XYUO6/`'Q;TWQA\*/'.IM\.?A-X2\-WV
MBZ3K7PV\=_#CP;X.T_PA:3VNKB>62]U=0#^O2BN5\"ZM9Z_X+\):]I_B/2_&
M5CKGAK0M8L_&&A_9O[$\66NIZ7:WMOXGT;['/=69TKQ!#-'JU@;2ZN;8VMY$
M8KB=,2OU5`!1110`UP"I!.!QD_B/Y]*AW1H#\Y^;CMVYY[]\GGOZ5+)]P_5?
M_0A5&Y^X>V$<\<="M*RUT7O*STU:[-[V!JXKPV[[V:4_."&#$8"G_8QLW`<"
M3;YNW"[]H`'@_P`7/V9/V=?CE;RQ?%3X5^!_%]S*GE+K-[H\%IXEMX@%"I9^
M*M+^P^)+-4,:%1:ZK"N57*G:NWUR\=XX_D8`N0&)&[C*@CD]",Y]SGZ^3^*K
MOQ>D<BZ-X@T_376-F1[G0!J07]ZJ`%1JEEN/N6Z94`9!'-B<!A,?2>'Q>%P^
M+I2CR.GBJ-/$0Y=+KEJQFDK+9;6T.;$8;#UZ<H5Z-*M%JS56$:FEUHN=2:6B
MVM8_./QY_P`$6?V8-<GFO?`GCWXN?#&\N999HX=*\0Z1KFF"1FW82/7]/.L8
MB7]W$T&OP38`,TLS_,?FG6/^"&GB^1+H:+^V=K)3R9$M;34_A7J:#>8V4I-<
MVWQ8+%>2P%M8-.&VF,;TR/T=OO$G[0R:I)';_%?P7'I_FNLEK+\)))II57=M
M5[E?B#"BA=N!Y=LAQ]XL>:]^\':EXUN[/S-<\1:5J;;$1A!X8BTY65VPRD)J
MER,,/O#D-R#P<5\5B/"?@+$S=6?#F!HU92<I5,'36'E)MIMRY)0LTXIQ<.6U
MW:U]?F,3P?PIB)J6(R>C[6;;C.@Y4[/W4[QYU#=Q:]W36UCX"^%G_!.'X_>&
MK?3O#?Q5_;3M?CW\,K&2T:\^&/Q>_9S\-?$O3_L]HJ1_9-&\3>-_B#XC\2^&
MH8UBACMUTUH4M?(6Y6UANYKEF]%\5?\`!*7]FF\\=^%_B5X`LV\%ZQX:UW3M
M>D\+ZAIUE\1/A;XBM[2827^CZYX(\6W<LOV._0RK;C2_$&D/IMR;>\M')M$A
M/Z36KR,D'FN78(#D`*%(X^11D(,*`.20,C.,`;*\G/K\K9Y+#:?O$\L/8YQV
MK]0X8SCB'@W"2R[AS/LZP&`J8>KA*F$6:8R=+ZM7I>QJTW"K7JPY72G*"48I
MJ,O=:=V>/FWA-X;9Y+!U<YX0R3-<=E]2&,P&89A@*.)S/"U*$J=:G[',IIXN
ME",J</W-.NJ#22E3EJG!IUA!;1):VJI;VEG%;V\%O;PQP00);JT!@AA4D00A
M8U*1(BQ("1$\N&8;$:;$"EBV,_,<9/.>U-B_BX`Y/08_B;^N3]234M><]92F
M]9S?-.76<MN:;7Q2MIS.\K=3]"H1C"G&$$HPC&G",(JT80IP4(1A%>[",8JR
MC%)=6F]0KX9_;H_90\4_M:>#_A'HG@;XOVGP2\;?!;]H;X=?M#>$?&6I?#*'
MXKZ5/K_P]T;Q=I6GZ'JGA"[\9^`K._L9)O%JZK*\^O2A?[/:%=-N#(9;?[FI
MI52<E5)(`)(!)`S@9QT&YL#_`&CZF@V/S"\(_L._';Q;\>O@O\:?VN/VN;']
MH"#]G76_$WC?X1>`/`7[.V@_`#PQ9_$KQ-X3O_`<WCGQC?6GQ)^)>L>,+O0/
M"NJZOI/A_2$N]`M]/N=2N;R\&I6S1VP_3N*,1+M#,W<LQR2<#+'``+,<NQQR
MS$^U/"J.@`QTP!QQC^7'TXI:`"JES.86B4*K"0GC)#%E>+:J]%^8,P!+9\SR
MU",'9DMTA56^\JMP1R`>#C(Y['`R.^!GI0!\H?L5?LXG]D/]F'X2?LX+XR;X
MA1_"W3-8TB+QD_AP>$GU]=4\4:YXE,QT%=>\2IIK6[:O);B,:S?+-#;QRF2&
M:62"+ZPIH5020J@D`$@`$@#`!(&<`<#T'`IU`!7Q'^UM^Q]-^T!JWPD^*WPV
M^*VN_`+]H[]G[5?$.H_"/XP:+H=KXNL+;2_&%E::?XS\!?$7P-?:CHUK\0?A
MMXN@T[3'UCPW-K.E7<5]IUCJ.EZI9W,<WVC[<HP#U&:`/S+^%W[&?QAUC]H'
MP+^T[^V#^T-H_P`>O'GP5T3Q?I'P'\!?#CX3+\(?A-\)M4\>V3Z#XQ\<_P!C
MWGC7QKX@\:_$?7/"K3^';;7-:U#3M*\.Z1>:A;6>C&X?^UG_`$PB*F*(H04,
M:%"K^8I4J"I$F6W@C!#[FW#YLG.:=L3CY%XZ?*.,``8XXP`!]`/2G4`%072>
M9:W,?'[R"9.4,@^>-EYC!!<<\H""WW<\U/00"""`01@@\@@]01W!H`_&']GG
M]@;]NG]E_P"%/@;X'?"S_@HA\,H/A?\`#J6\71=+U[]A+1M;UL:7K'C/5_%.
MHPWGB:[_`&H(S<7=Q>ZMK/E7YLV>T2:"1;)IH/LT_P"R5@DD=K&DS%Y5&)'9
M)4WR``22!)F=T623=(D>]UB5Q$CLB`FUL3.[8N[GYMHSR,'G&>1P?4<&E``&
M```.@`P!^`H`6H9(0Y+*[1OM*AU"DJ0KA&"N&3*&1F&5(8X#!E&*FHH`_*!?
MV&?VCO@KXM^*1_8F_:Y\+?`[X2_%WQSX@^(VJ?!WXI_L^V7QLT7X6_$CQWJ4
MVL^.?%7P5U&+XB_#R?0M+\3:]*WB:;X;Z[;:KX:MO$USJ6KV5W9PZC/:'ZY_
M9!_9@\+?LG?"B7X>:+XC\2^/_%?B3Q9XE^)_Q=^*_CA["3QS\7/BYX]U!]4\
M:>/_`!2=,CBT^"ZU*Y6"PTO3K!&L=%T#3-*T6&XNWT^:[F^H_+CSG8F<%<[5
MSM8DE<XZ$DDCH223UIP5020`">20`"2!@$XZX''/;B@!:***`/D']L7]E;1_
MVJ_!'A;1T\;>)?A+\3OA9X\T/XL?`[XT>"K?3;GQ7\,?B5X<AO(+/5[:QU5X
M;#Q%X=U;3-0U+0/&O@S4YH=(\4^'=0FLKB[M+N*TNK3XX\:_L#_M7_'SQC\"
M?%_[4/[;^C^*]+_9Q_:"^$'Q[\"?#SX.?L_6GPP\%>*->^$_C/3?$5U/\3%U
MKXM^+=<U_6/$>CV6I:+X>@L-3T_0/AS?ZU=:W'IOB]HK>WB_83`]!R03P.HZ
M'ZC`P>V*-J_W1V[#MG'Y9./J?6@"M:OO63_9E8=&49(5R0KJI`8OOP-P`8#.
MX,HM4U55!M155<D[5`498EF.``,EB23W))/)IU`%2ZE:(1[%#,S@*")#EB55
M5_=H[8.XEV"L8D#3,ICC?'RW^RO^SN?V;-%^,&BKXQ_X38_%K]I3XW?M"M<G
MP_%X>_L(_&7Q=)XEE\*QPP^(?$7]I0^&VD^PKKIFLY=6+I/)HNE!70?5S*K`
MAE#`C!#`$$'J"#P0<#CVI-J[MVU=QX+8&X@=!G&?UH`=1110!\@?M@_LEZ7^
MU1X*\&VECX^\2?"'XL?"+XD>'_C#\#_C-X2LM/U77_AM\1_#UI>:5'?G1-6:
M+3?$OAKQ%X?U+5O"OC/PG?W=C:>(O#FKW]D;ZQN7ANXOG;P;^Q+\>_'7QI^#
MWQA_;/\`VG?"_P`=;?\`9VU'6O%'P9^&'PO^!MM\%O`%O\4=3T"[\+I\7?'0
MN_'OC[6/%?BS0]"U'4U\(Z79R:%HOA/4-0FU2QN=1N'`@_4=E5@590RD8*L`
M01Z$'((^M)L3^ZO;^$?P].W;MZ=J`!""BE3E2JE3NW9!`P=V6W9'\6XYZY.<
MTZBB@"GJ-G::CI]]I^H6Z7=A?6=U9WMK+CR[FTNH'@N;>3+(-DT+O&^64;6.
M67J/QHM/^"=W[67@WX-ZU^R/\.?V][+2?V1[_P`,Z_\`#O1=+\7_`+.^C^,_
MVB?`7P@\1)J.G7?PUT+XP7?Q,TWP[KB6^AZO<^'O#?C;Q3X`;6_#.EV&G(^G
M^(KJV6\/[1TT(BC"HJ@#``4`8YXP!C')X]S0!P'PF^'7ACX0?"_X=?"3P3!<
MVO@OX6>!O"7PW\(6M[=RW][;>%O`OA_3O"WA^WO;^8"6_NX=)TJT2YO9%5KJ
?56F(R^3Z#2!57A0%!))``&23DGCN3R3U)Y-+0!__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
